About Us

Leadership Team

Our senior management team’s leadership and vision are critical to the company’s operational efficiency and growth, positioning us well to continue bringing important therapeutics to patients in need.

William K. Heiden
President and Chief Executive Officer
William Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer of AMAG since May 2012 and...
William Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer of AMAG since May 2012 and served as president from May 2012 through April 2015. Mr. Heiden joined AMAG from GTC Biotherapeutics, Inc. (now rEVO Biologics, Inc.), where he was president and chief executive officer from 2010 to 2012 and chairman of the board of directors from 2007 to 2013. From 2004 to 2008, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals. Prior to that, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (now GlaxoSmithKline plc). Mr. Heiden also held various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. He currently serves on the board of directors for Atara Biotherapeutics, Inc. Mr. Heiden holds a Bachelor of Arts degree from the University of Florida, a Master of Information Management from the University of Louvain, and a Master of Business Administration from Cornell University’s Johnson Graduate School of Management.
Peter Bawin
Senior Vice President and General Manager for Cord Blood Registry
Peter Bawin serves as senior vice president and general manager for Cord Blood Registry (CBR). Mr. Bawin joined CBR in 2009 and held...
Peter Bawin serves as senior vice president and general manager for Cord Blood Registry (CBR). Mr. Bawin joined CBR in 2009 and held leadership roles of increasing responsibility before the company was acquired by AMAG in 2015. With more than 15 years of healthcare, pharmaceutical, consumer, digital marketing and sales experience, Mr. Bawin previously held product management roles within Mylan's EpiPen business and began his career as a pharmaceutical sales representative with the allergy and cardiovascular franchises at Schering-Plough. Mr. Bawin holds a Bachelor of the Arts degree from Miami University and a Master of Business Administration degree from University of Denver.
Elizabeth Bolgiano
Executive Vice President, Chief Human Resources Officer
Elizabeth Bolgiano is an experienced human resources professional who joined AMAG in January 2014 as senior vice president of human...
Elizabeth Bolgiano is an experienced human resources professional who joined AMAG in January 2014 as senior vice president of human resources. Ms. Bolgiano joined AMAG from Thermo Fisher Scientific where she was senior vice president of human resources and a member of the executive team. Prior to Thermo Fisher Scientific, Ms. Bolgiano served as group human resources director of Smith & Nephew Company. From 1989 to 2004, Ms. Bolgiano progressed through various positions of increasing responsibility at Bristol-Myers Squibb Company. She holds Master of Business Administration and Bachelor of Science degrees from Cornell University.
J. Alan Butcher
Executive Vice President & Chief Business Officer
Alan Butcher serves as AMAG’s executive vice president and chief business officer. He joined AMAG in April 2018 and brings more than 20...
Alan Butcher serves as AMAG’s executive vice president and chief business officer. He joined AMAG in April 2018 and brings more than 20 years of extensive technical, scientific, strategic, and business development experience from large and medium-sized pharmaceutical companies. He joins AMAG from Purdue Pharma where he served as senior vice president, licensing and business development. Prior to Purdue, he led a global business development team and was responsible for identifying, evaluating and negotiating expansion opportunities at Shire Pharmaceuticals. Mr. Butcher holds a Bachelor’s of Science in Clinical Microbiology and a Master’s of Science in Biology with a concentration in Molecular Biology and Genetics from West Chester University of Pennsylvania. He is also a graduate of Cornell University’s Johnson Graduate School of Management.
Tony Casciano
Senior Vice President, Specialty Products Sales and Marketing
Tony Casciano serves as AMAG’s senior vice president of specialty products sales and marketing. He joined AMAG in September 2016 and...
Tony Casciano serves as AMAG’s senior vice president of specialty products sales and marketing. He joined AMAG in September 2016 and brings more than 16 years of commercial sales and marketing experience. Mr. Casciano joined AMAG from Sanofi where he most recently served as the head of marketing for General Medicines. During his career at Sanofi US, he held multiple commercial leadership roles throughout the organization and across a broad range of departments and therapeutic areas. During his tenure at Sanofi, he was responsible for building and leading top-performing cross functional commercial teams to achieve aggressive goals for more than 16 specialty brands.
Shannon Gath
Vice President, Head of AMAG Technology
Shannon Gath is vice president and oversees the company’s information technology operations.  She joined AMAG in 2017 as vice president...
Shannon Gath is vice president and oversees the company’s information technology operations.  She joined AMAG in 2017 as vice president of strategic technologies with more than 20 years’ experience in information technology.  Prior to joining AMAG, Shannon held positions of increasing responsibility at Fidelity and Vertex, where she was responsible for driving transformational changes and executing market-leading technology and digital strategies.  Shannon began her career as a mechanical engineer at Empirix, and she holds a bachelor’s of science in mechanical engineering from Tufts University.

 

 
Nicholas Grund
Executive Vice President and Chief Commercial Officer
Nicholas Grund serves as AMAG’s executive vice president, and chief commercial officer. He joined AMAG in January 2016 and brings more...
Nicholas Grund serves as AMAG’s executive vice president, and chief commercial officer. He joined AMAG in January 2016 and brings more than 20 years of commercial leadership experience in the biopharmaceutical industry, including several global senior-level executive roles in sales and marketing. He joins AMAG from Genzyme Corporation, a Sanofi Company, where he spent the past 13 years in business leadership roles, most recently as the leader of the company’s rare disease and multiple sclerosis franchises in Asia Pacific and Canada. Mr. Grund joined Genzyme from Bayer Diagnostics where he progressed through a number of senior finance roles in the critical care business unit from 1995 to 2002. Mr. Grund holds a Bachelor of Science degree in business administration from the University of Massachusetts and a Master of Business Administration degree from Northeastern University.
Kyle Haraldsen
Vice President of Technical Operations and Project Management
Kyle Haraldsen serves as AMAG’s vice president of technical operations and project management. He rejoined the company in November 2013...
Kyle Haraldsen serves as AMAG’s vice president of technical operations and project management. He rejoined the company in November 2013 and brings more than 15 years of pharmaceutical manufacturing experience to this role, including marketing authorization approvals in both the US and EU. Prior to returning to AMAG, he was the Senior Director, Manufacturing at Radius Health and was directly responsible for the abaloparatide CMC programs. Mr. Haraldsen previously worked at AMAG between 2009 and 2012, and also worked at Avecia Biotechnology and Johnson Matthey with increasing responsibilities in both manufacturing and project management.  He holds a Bachelor of Science degree in chemical engineering from Northeastern University.
Julie Krop, M.D.
Executive Vice President, Chief Medical Officer
Julie Krop, M.D. serves as AMAG’s chief medical officer and executive vice president of clinical development and regulatory affairs. She...
Julie Krop, M.D. serves as AMAG’s chief medical officer and executive vice president of clinical development and regulatory affairs. She joined AMAG in June 2015 and has more than 15 years of experience in drug development. Dr. Krop most recently worked for Vertex Pharmaceuticals, where she served as vice president of clinical development. She began her career in the biopharmaceutical industry in 1991 at Pfizer, Inc. and has since held various leadership positions at Stryker Regenerative Medicine, Peptimmune, and Millennium Pharmaceuticals. Dr. Krop received a Bachelor of Science degree from Brown University and a medical degree from the Brown University School of Medicine. She completed her residency in the Department of Medicine at Georgetown University Hospital and a fellowship in the Department of Endocrinology at The Johns Hopkins University School of Medicine. In addition, Dr. Krop was a Robert Wood Johnson Foundation Clinical Scholar.
Edward (Ted) Myles
Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Ted Myles joined AMAG in 2016 and brings more than 20 years of public and private corporate finance and operational experience in the...
Ted Myles joined AMAG in 2016 and brings more than 20 years of public and private corporate finance and operational experience in the biotechnology, pharmaceutical and medical device industries. Prior to joining AMAG, he served in various positions at Ocata Therapeutics, Inc., most recently as chief financial officer and chief operating officer. During his tenure at Ocata, he led the turnaround of the company, which ultimately resulted in its acquisition by Astellas Pharma in February 2016. From 2008 to 2013, Mr. Myles served as chief financial officer and vice president of operations at PrimeraDx, Inc. Prior to that, Mr. Myles was senior vice president of finance and chief financial officer of Pressure Biosciences, Inc. and also served as controller at EMD Pharmaceuticals, Inc., a wholly-owned subsidiary of Merck KGaA. Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation and served as corporate controller for Boston Biomedica, Inc. Mr. Myles became a certified public accountant in 1996 and began his career in 1993 at PriceWaterhouseCoopers LLP. Mr. Myles holds a Bachelor of Science degree in Business Administration from the University of Hartford and a Master of Business Administration from John M. Olin School of Business at Washington University.
Kathryn Carr Payne
Senior Vice President, Corporate Affairs
Kathryn Payne serves as AMAG’s senior vice president of corporate affairs and oversees the company’s communications, policy and...
Kathryn Payne serves as AMAG’s senior vice president of corporate affairs and oversees the company’s communications, policy and advocacy activities. She joined AMAG in May 2014 from APCO Worldwide, a global public affairs and strategic communications firm based in Washington D.C. There, she spent 10 years in various positions of increasing responsibility, including most recently as a vice president and director of the healthcare practice group. Prior to joining APCO, Ms. Payne served as a communications associate at the World Bank in Washington, D.C., and as a healthcare research associate at Forrester Research, a publicly traded research and advisory firm. Ms. Payne graduated Phi Beta Kappa and with high honors from The Johns Hopkins University with a Bachelor of Science degree in writing and business management and a master’s degree in communications.
Joseph D. Vittiglio
Executive Vice President, General Counsel, Quality & Corporate Secretary

Joseph Vittiglio serves as AMAG’s executive vice president, general counsel and quality and corporate...

Joseph Vittiglio serves as AMAG’s executive vice president, general counsel and quality and corporate secretary. Before joining AMAG, he served as vice president of legal affairs and a member of the management committee at Flexion Therapeutics, Inc. Prior to that, Mr. Vittiglio was the general counsel of AVEO Pharmaceuticals and the director of legal affairs at Oscient Pharmaceuticals Corporation. He began his legal career as an associate attorney at Gaffin & Krattenmaker, P.C., before joining Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC as a senior attorney in 1998. Mr. Vittiglio holds a Bachelor of Science degree in international relations from Tufts University and a Juris Doctor from Northeastern University School of Law.

Paul Williams
Senior Vice President of Sales and Marketing, Women’s Health
Paul Williams serves as senior vice president of sales and marketing for the women’s health division of AMAG. Mr. Williams joined AMAG in...
Paul Williams serves as senior vice president of sales and marketing for the women’s health division of AMAG. Mr. Williams joined AMAG in November 2014 as part of the company’s acquisition of Lumara Health with more than 25 years of sales and marketing experience. As vice president of the women’s healthcare division and commercial operations of Lumara Health, he led the planning and relaunch of the company’s product portfolio in anti-infectives and hormone replacement therapy. Prior to joining Lumara Health, Mr. Williams served as senior vice president and general manager of a division of Actavis, Inc. Mr. Williams has also held positions of increasing responsibility in sales and marketing at Medimmune LLC (a member of the AstraZeneca Group) and Centocor, Inc. (a Johnson & Johnson Company). Mr. Williams holds a Bachelor of Science degree in finance from Virginia Polytechnic Institute and State University.